How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem

Simply Wall St.05-22

On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637987360?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-05-22 11:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637987360","market":"hk","top_or_hot":-1,"title":"How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem","media":"Simply Wall St.","content":"<div>\n<p>On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-resmedoura-wearable-sleep-data-partnership-could-reshape\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-22 11:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-resmedoura-wearable-sleep-data-partnership-could-reshape><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-resmedoura-wearable-sleep-data-partnership-could-reshape\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2008162690.USD","symbol_name":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-resmedoura-wearable-sleep-data-partnership-could-reshape","article_id":"2637987360","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-resmedoura-wearable-sleep-data-partnership-could-reshape","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637987360","pubTimestamp":1779420940,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent healthcare providers.\nThis collaboration uniquely bridges consumer wearable sleep data with clinical sleep resources, aiming to help address undiagnosed conditions such as obstructive sleep apnea.\nNext, we’ll examine how integrating Oura’s consumer wearables data with ResMed’s clinical sleep...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","RMD.AU":"Resmed DRC","BK4504":"桥水持仓","RMD":"瑞思迈","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK7501":"新冠治疗股","BK4548":"巴美列捷福持仓","BK7007":"医疗保健设备","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4588":"碎股","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"瑞思迈与Oura可穿戴睡眠数据合作伙伴关系如何重塑瑞思迈(RMD)临床生态系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":1.5,"RMD":0.9},"content_text":"On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent healthcare providers. This collaboration uniquely bridges consumer wearable sleep data with clinical sleep resources, aiming to help address undiagnosed conditions such as obstructive sleep apnea. Next, we’ll examine how integrating Oura’s consumer wearables data with ResMed’s clinical sleep ecosystem could influence the company’s investment narrative. Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.AdvertisementResMed Investment Narrative RecapTo own ResMed, you need to believe in a long runway for sleep apnea diagnosis and home-based, cloud-connected therapy, supported by resilient margins. The Oura partnership fits this by nudging more undiagnosed consumers into ResMed’s funnel, but it does not directly change near term exposure to reimbursement shifts or competition from alternative therapies, which still look like the most important catalyst and risk for the stock over the next year. The ResMed and Oura tie up also sits alongside another recent development: Q3 FY26 results showed US$1,431.4 million in sales and US$398.7 million in net income, with ongoing buybacks and a US$0.60 quarterly dividend. Together, these updates frame how investors might think about balancing potential upside from a broader digital ecosystem with ongoing concerns about pricing pressure, cost inflation and evolving reimbursement for sleep and respiratory care. Yet while partnerships like Oura could expand the funnel, investors still need to think carefully about the risk that tighter reimbursement or new cost controls... Read the full narrative on ResMed (it's free!)ResMed’s narrative projects $6.7 billion revenue and $1.9 billion earnings by 2029. This requires 7.6% yearly revenue growth and an earnings increase of about $0.4 billion from $1.5 billion today.Uncover how ResMed's forecasts yield a $288.21 fair value, a 38% upside to its current price.Exploring Other PerspectivesRMD 1-Year Stock Price Chart Some of the most optimistic analysts saw ResMed reaching about US$7.0 billion in revenue and US$2.1 billion in earnings by 2029, which is a far more upbeat view than consensus and assumes smoother execution on catalysts like expanding sleep screening links than the baseline narrative. With the Oura news still fresh and not yet reflected in those forecasts, you should expect that opinions on both the upside and the risks could shift as more data comes through.Explore 8 other fair value estimates on ResMed - why the stock might be worth 14% less than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.Interested In Other Possibilities?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Find 53 companies with promising cash flow potential yet trading below their fair value.Uncover the next big thing with 28 elite penny stocks that balance risk and reward.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637987360","isCrawlerRequest":true}